Avastin fails only Phase III trial in advanced prostate cancer
This article was originally published in Scrip
Executive Summary
Roche's Avastin (bevacizumab), the world's best-selling cancer drug, has failed to prolong overall survival in its only Phase III trial in advanced prostate cancer, CALGB 90401, which was sponsored by the US National Cancer Institute (NCI).